Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.48 |
| ▸ | TTK | P33981 | 8/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 3/20 | 0.39 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25232043 | 0.91 | IKBKB (0.43) | PIM1TTKIKBKB | |
| SCHEMBL25276098 | 0.88 | TTK (0.44) | PIM1TTKPIM2IKBKB | |
| SCHEMBL25277050 | 0.85 | CNR1 (0.42) | TTKIKBKB | |
| SCHEMBL30968211 | 0.81 | HCAR3 (0.41) | HCAR3 | |
| SCHEMBL25274583 | 0.81 | HCAR3 (0.41) | HCAR3 | |
| SCHEMBL25277007 | 0.80 | HPGD (0.41) | PIM1TTKPIM2PRKCQ | |
| SCHEMBL25235225 | 0.78 | TTK (0.38) | PIM1TTKPIM2PRKCQ | |
| SCHEMBL25275415 | 0.72 | CCNE1 (0.47) | TTK | |
| SCHEMBL3313550 | 0.70 | TYK2 (0.58) | TTK | |
| SCHEMBL25279450 | 0.70 | HPGD (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-15 | — | — | US | disclosed |
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183242-A1 | IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | TYK2, JAK3, IFNAR1 | PIM1 305/4885TTK 126/4885CRHR1 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.